[Letter: Narcolepsy. Suppression of paradoxical sleep by L-dopa].
D002395:Catecholamines / Q000032:analysis; D003534:Cyproterone / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009290:Narcolepsy / Q000188:drug therapy*; D012701:Serotonin / Q000032:analysis; D012895:Sleep, REM / Q000187:drug effects*; D014642:Vanilmandelic Acid / Q000652:urine
D002395:Catecholamines; D012701:Serotonin; D007980:Levodopa; D006897:Hydroxyindoleacetic Acid; D014642:Vanilmandelic Acid; D003534:Cyproterone; D006220:Haloperidol; D006719:Homovanillic Acid
Narcolepsie. Suppression du sommeil paradoxal par la l-dopa